Results from Sanofi’s Kevzara trial allows a more targeted approach for its final stages

30 April 2020 (Last Updated April 30th, 2020 16:34)

On 27 April, Regeneron and Sanofi published provisional results from the Phase II section of an ongoing Phase II/III clinical trial assessing Kevzara (sarilumab), in hospitalised patients with severe or critical respiratory illness caused by Covid-19.

The randomised trial compared the drug, administered intravenously at two different doses of 200mg and 400mg, with placebo. Read more here.